Biodexa Pharmaceuticals Launches Phase 3 Trial of eRapa for FAP, Aiming for First Mover Advantage in $7 Billion Market
Reuters
Sep 08
Biodexa Pharmaceuticals Launches Phase 3 Trial of eRapa for FAP, Aiming for First Mover Advantage in $7 Billion Market
Biodexa Pharmaceuticals PLC has announced the commencement of its Phase 3 clinical trial for eRapa, a proprietary encapsulated form of rapamycin, aimed at treating familial adenomatous polyposis (FAP). This trial follows a successful Phase 2 trial, which showed a median decrease in overall polyp burden of 29% and a non-progression rate of 89% at 12 months in the dosage regimen selected for Phase 3. The double-blind, placebo-controlled trial involves 168 patients and is being conducted across approximately 30 clinical sites in the U.S. and Europe. The study is supported by a $20 million grant from the Cancer Prevention & Research Institute of Texas, with management of the U.S. and European components by LumaBridge and Precision for Medicine LLC, respectively. The results of the Phase 3 trial are yet to be presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069300) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.